- Navigating Your Midlife Crisis: Embracing New Possibilities
- City Raccoons Showing Signs of Domestication
- Mapping the Exposome: Science Broadens Focus to Environmental Disease Triggers
- One Week Less on Social Media Linked to Better Mental Health
- Your Brain Changes in Stages as You Age, Study Finds
- Some Suicide Victims Show No Typical Warning Signs, Study Finds
- ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism
- Switch to Vegan Diet Could Cut Your Greenhouse Gas Emissions in Half
- Regular Bedtime Does Wonders for Blood Pressure
- Dining Alone Could Mean Worse Nutrition for Seniors
1st HPV Test for Use With Preservative Fluid
The U.S. Food and Drug Administration has approved Roche’s cobas HPV Test — the first diagnostic to be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid.
SurePath is an FDA-approved liquid collection fluid that’s frequently used for Pap tests. But until this latest approval, no human papillomavirus (HPV) test had been approved to be used with the fluid, the FDA said in a news release.
HPV strains account for some 70 percent of cervical cancers globally. The U.S. National Cancer Institute estimates there will be nearly 13,000 new cases of cervical cancer detected this year, and the disease will cause more than 4,100 deaths.
The Swiss drugmaker Roche in 2012 warned that using cervical cells in SurePath fluid with an existing HPV test could produce false-negative results, the FDA said. This could have led to lack of treatment and cervical cancer progression among women who obtained false-negatives.
More information
Learn more about this approval from the FDA.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.










